



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6978)

Hong Kong Branch Share
Registrar and transfer office
Computershare Hong Kong
Investor Services Limited
Shops 1712-1716, 17/F
Hopewell Centre
183 Queen's Road East
Wanchai, Hong Kong

RIGHTS ISSUE ON THE BASIS OF ONE (1) RIGHTS SHARE FOR EVERY FIVE (5) EXISTING SHARES HELD ON THE RECORD DATE AT THE SUBSCRIPTION PRICE OF HK\$2.5 PER RIGHTS SHARE PAYABLE IN FULL ON ACCEPTANCE BY NO LATER THAN 4:00 P.M. ON TUESDAY, 4 NOVEMBER 2025

Registered office:
P.O. Box 309
Ugland House
Grand Cayman KY1-1104
Cayman Islands

Principal place of business
in Hong Kong:
31/F, Tower Two,
Times Square
1 Matheson Street
Causeway Bay
Hong Kong

EXCESS APPLICATION FORM

Name(s) and address of Qualifying Shareholder(s)

14 October 2025

Application can only be made by the
Qualifying Shareholder(s) named here.

Total number of Excess Rights Share(s) Applied

BOX A

Total subscription monies paid for the Excess
Rights Shares in HK\$

BOX B

Note: All remittances must be made in Hong Kong dollars and cheques must be drawn on an account with, or banker's cashier orders must be issued by, a licensed bank in Hong Kong and made payable to "IMMUNOTECH BIOPHARM LTD – EAF" and crossed "Account Payee Only". All cheques or banker's cashier orders will be presented for payment following receipt.

To The Directors,
Immunotech Biopharm Ltd

Dear Sirs,

I/We, being the registered holder(s) named above of the Shares, hereby irrevocably apply for excess Rights Share(s) (write the number of shares in Box A) at the Subscription Price of HK\$2.5 per Rights Share under the Rights Issue in respect of which I/we enclose a separate remittance by cheque or banker's cashier order in favour of "IMMUNOTECH BIOPHARM LTD – EAF" and crossed "Account Payee Only" issued for HK\$ (write the full amount in Box B) being payment in full on application for the aforementioned number of excess Rights Shares. I/We hereby request you to allot such excess Rights Shares applied for, or any lesser number, to me/us and to send by ordinary post at my/our risk to my/our address shown on the register of members of the Company my/our share certificate(s) for the number of excess Rights Shares as may be allotted to me/us in respect of this application and/or a cheque for any application money refundable to me/us. I/We understand that allotment in respect of this application shall be made by the Directors that any excess Rights Shares will be allocated to Qualifying Shareholders who apply for them on a pro rata basis on the number of excess Rights Shares applied for, without involving allocation of any fractional Rights Share. No preference will be given to application made for topping up odd lots holding to whole board lots holding. I/We acknowledge that I am/we are not guaranteed to be allotted all or any of the excess Rights Shares applied for.

I/We, hereby undertake to accept such number of excess Rights Shares as may be allotted to me/us as aforesaid upon the terms set out in the Prospectus and subject to the memorandum and articles of association of the Company. In respect of any excess Rights Shares allotted to me/us, I/we authorise you to place my/our name(s) on the register of members of the Company as holder(s) of such Rights Shares.

1

2

3

4

Signature(s) of applicant(s) (all joint applicants must sign)

Name of bank on which
cheque/banker's cashier order is drawn: _____

Cheque/banker's cashier order number: _____

Date: _____ 2025

Contact Tel No: _____

A SEPARATE CHEQUE OR BANKER'S CASHIER ORDER MUST ACCOMPANY EACH APPLICATION
NO RECEIPT WILL BE GIVEN FOR REMITTANCE

CCS3487 ITBH



Immunotech Biopharm Ltd

永泰生物製藥有限公司

(於開曼群島註冊成立的有限公司)

(股份代號：6978)

香港股份過戶登記分處
香港中央證券登記有限公司
香港灣仔
皇后大道東183號
合和中心
17樓1712-1716號舖

按於記錄日期每持有五(5)股現有股份
獲發一(1)股供股股份之基準
以認購價每股供股股份2.5港元
進行之供股
股款須不遲於2025年11月4日(星期二)
下午四時正接納時繳足

註冊辦事處：
P.O. Box 309
Ugland House
Grand Cayman KY1-1104
Cayman Islands

香港主要營業地點：
香港
銅鑼灣
勿地臣街1號
時代廣場二座31樓

額外申請表格

合資格股東的姓名／名稱及地址

只供本欄所指定的合資格股東作出申請。

所申請額外供股股份總數

甲欄

額外供股股份的應繳認購股款總額(港元)

乙欄

附註：所有股款須以港元繳付，並以香港持牌銀行戶口開出的支票或以香港持牌銀行發出的銀行本票支付，且均須註明抬頭人為「IMMUNOTECH BIOPHARM LTD – EAF」並以「只准入抬頭人賬戶」方式劃線開出。所有支票或銀行本票收訖後將隨即過戶。

致 永泰生物製藥有限公司
列位董事

敬啟者：

本人／吾等為上文列明的股份登記持有人，現不可撤回地根據供股以每股供股股份2.5港元的認購價申請認購(填寫股份數目於甲欄)額外供股股份，並隨附另行繳付款項為(填寫總金額於乙欄)港元的支票或銀行本票，註明抬頭人為「IMMUNOTECH BIOPHARM LTD – EAF」及以「只准入抬頭人賬戶」方式劃線開出，作為申請認購上述數目額外供股股份須全數支付的股款。本人／吾等謹要求閣下配發予本人／吾等所申請(或任何較少數目)的額外供股股份，並按貴公司股東名冊所示之本人／吾等之地址將本人／吾等就本申請所獲配發的額外供股股份數目的股票及／或任何有關應退還予本人／吾等的申請款項的支票以平郵投遞方式寄予本人／吾等，郵誤風險概由本人／吾等自行承擔。本人／吾等明白，董事將按已作出本申請之合資格股東所申請之額外供股股份數目按比例向彼等配發額外供股股份，當中不會涉及分配任何零碎供股股份。概不會優先處理旨在將碎股補足為完整買賣單位作出之申請。本人／吾等確悉本人／吾等未必可獲保證配發全部或任何部分所申請認購之額外供股股份。

本人／吾等承諾接納按供股章程所載條款及在貴公司的組織章程大綱及章程細則規限下可能配發予本人／吾等的上述額外供股股份的數目。就配發予本人／吾等的任何額外供股股份而言，本人／吾等授權閣下將本人／吾等的姓名列入貴公司股東名冊作為該等供股股份的持有人。

1

2

3

4

申請人簽署(所有聯名申請人均須簽署)

支票／銀行本票的付款銀行名稱：_____

支票／銀行本票號碼：_____

日期：2025年_____月_____日

聯絡電話號碼：_____

每份申請須隨附獨立開出的支票或銀行本票
所有繳款將不獲發收據

CCS3487 ITBH

IMPORTANT

Reference is made to the prospectus issued by Immunotech Biopharm Ltd (the “**Company**”) dated 14 October 2025 in relation to the Rights Issue (the “**Prospectus**”). Terms defined in the Prospectus shall have the same meanings when used herein unless the context otherwise requires.

THIS EXCESS APPLICATION FORM (“EAF”) IS VALUABLE BUT IS NOT TRANSFERABLE AND IS ONLY FOR THE USE BY THE QUALIFYING SHAREHOLDER(S) NAMED OVERLEAF WHO WISH(ES) TO APPLY FOR THE EXCESS RIGHTS SHARES IN ADDITION TO THOSE RIGHTS SHARES PROVISIONALLY ALLOTTED TO HIM/HER/IT/THEM. THIS EAF REQUIRES YOUR IMMEDIATE ATTENTION. THE OFFER CONTAINED IN THIS EAF AND THE ACCOMPANYING PAL EXPIRES AT 4:00 P.M. ON TUESDAY, 4 NOVEMBER 2025 (OR, UNDER BAD WEATHER CONDITIONS, SUCH LATER DATE AS MENTIONED IN THE PARAGRAPH HEADED “EFFECT OF BAD WEATHER” IN THE ENCLOSED SHEET).

IF YOU ARE IN ANY DOUBT AS TO ANY ASPECT OF THIS EAF OR AS TO THE ACTION TO BE TAKEN, YOU SHOULD CONSULT YOUR LICENSED SECURITIES DEALER, BANK MANAGER, SOLICITOR, PROFESSIONAL ACCOUNTANT OR OTHER PROFESSIONAL ADVISERS.

A copy of the Prospectus, together with copies of the PAL, this EAF and other documents specified in the section headed “General Information – 14. Documents delivered to the Registrar of Companies” in Appendix III to the Prospectus, have been registered by the Registrar of Companies in Hong Kong pursuant to section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The Registrar of Companies in Hong Kong, the Stock Exchange and the SFC take no responsibility as to the contents of any of the documents referred to above.

Dealings in the Shares and the Rights Shares in their nil-paid form and fully-paid form may be settled through CCASS operated by HKSCC and you should consult your licensed securities dealer, bank manager, solicitor, professional accountant or other professional advisers for details of those settlement arrangements and how such arrangements may affect your rights and interests.

Subject to the granting of the listing of, and permission to deal in, the Rights Shares in both their nil-paid and fully-paid forms on the Stock Exchange as well as compliance with the stock admission requirements of HKSCC, the Rights Shares in both their nil-paid and fully-paid forms will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the commencement dates of the dealings in the Rights Shares in both their nil-paid and fully-paid forms or such other dates as may be determined by HKSCC. Settlement of transactions between participants of the Stock Exchange on any trading day is required to take place in CCASS on the second trading day thereafter. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time.

Hong Kong Exchanges and Clearing Limited, the Stock Exchange and HKSCC take no responsibility for the contents of this EAF, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this EAF.

The Rights Issue is conditional upon the fulfillment of the conditions set out under the section headed “Letter from the Board – Conditions of the Rights Issue” in the Prospectus.

The Underwriting Agreement contains provisions granting the Underwriter a right to terminate its obligations on the occurrence of certain events, which are set out in the section headed “Termination of the Underwriting Agreement” in the Prospectus. If the Underwriting Agreement does not become unconditional or is terminated in accordance with its terms, the Rights Issue will not proceed. Please refer to the section headed “Letter from the Board – Conditions of the Rights Issue” in the Prospectus for further details of the conditions of the Rights Issue.

The Shares have been dealt with on an ex-rights basis from Thursday, 2 October 2025. Dealings in the Rights Shares in the nil-paid form are expected to take place from Thursday, 16 October 2025 to Thursday, 30 October 2025 (both dates inclusive). If the conditions of the Rights Issue are not fulfilled or the Underwriting Agreement is terminated by the Underwriter on or before 4:00 p.m. on Thursday, 6 November 2025 or such later date as may be agreed between the Company and the Underwriter, the Rights Issue will not proceed. Any Shareholders or other persons dealing or contemplating dealing in the Shares up to the date on which all the conditions of the Rights Issue are fulfilled (and the date on which the Underwriter’s right of termination of the Underwriting Agreement ceases), and any dealings in the nil-paid Rights Shares between Thursday, 16 October 2025 to Thursday, 30 October 2025 (both dates inclusive), shall bear the risk that the Rights Issue may not become unconditional or may not proceed. Any Shareholders or other persons dealing or contemplating dealing in the Shares or nil-paid Rights Shares are recommended to consult their own professional advisers.

This EAF and all applications pursuant to it shall be governed by and construed in accordance with the laws of Hong Kong.

重要提示

茲提述永泰生物製藥有限公司(「本公司」)於2025年10月14日就供股刊發的章程(「供股章程」)。除非文義另有所指，否則供股章程所界定的詞彙與本表格所採用者具有相同涵義。

本額外申請表格(「額外申請表格」)具有價值，但不可轉讓，並僅供背頁列明且有意申請認購除暫定配發的供股股份以外的額外供股股份的合資格股東使用。本額外申請表格應即時處理。本額外申請表格及隨附的暫定配額通知書所載的要約將於**2025年11月4日(星期二)**(或於惡劣天氣情況下，附頁「惡劣天氣之影響」一段所述之較後日期)下午四時正截止。

閣下如對本額外申請表格的任何方面或將要採取的行動有任何疑問，應諮詢閣下之持牌證券交易商、銀行經理、律師、專業會計師或其他專業顧問。

供股章程文本連同暫定配額通知書、本額外申請表格及供股章程附錄三「一般資料—14.送呈公司註冊處處長之文件」一節內所指明的其他文件，已遵照香港法例第32章公司(清盤及雜項條文)條例第342C條的規定送呈香港公司註冊處處長登記。香港公司註冊處處長、聯交所及證監會對上文所述的任何文件的內容概不負責。

股份以及未繳股款及繳足股款供股股份的買賣可通過香港結算營運的中央結算系統結算。閣下應諮詢閣下的持牌證券交易商、銀行經理、律師、專業會計師或其他專業顧問，以了解結算安排詳情以及有關安排可能如何影響閣下的權利及權益。

待未繳股款及繳足股款供股股份獲准於聯交所上市及買賣，並符合香港結算的股份收納規定後，未繳股款及繳足股款供股股份將獲香港結算接納為合資格證券，可自未繳股款及繳足股款供股股份開始買賣當日或香港結算釐定的其他日期起，在中央結算系統寄存、結算及交收。聯交所參與者間於任何交易日進行的交易須於其後第二個交易日在中央結算系統進行交收。中央結算系統的一切活動均須依照不時生效的中央結算系統一般規則及中央結算系統運作程序規則進行。

香港交易及結算所有限公司、聯交所及香港結算對本額外申請表格的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本額外申請表格全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。

供股須待供股章程所載「董事會函件—供股的條件」一節所載條件達成後，方告作實。

包銷協議載有條文，賦予包銷商權利於發生若干事件時終止其責任，該等事件載於供股章程「終止包銷協議」一節。倘若包銷協議並未成為無條件或根據其條款終止，則供股將不會進行。供股之條件的進一步詳情，請參閱供股章程「董事會函件—供股的條件」一節。

股份已自**2025年10月2日(星期四)**起按除權基準進行買賣。未繳股款供股股份預期將於**2025年10月16日(星期四)**至**2025年10月30日(星期四)**期間(包括首尾兩日)買賣。倘於**2025年11月6日(星期四)**(或本公司與包銷商可能協定之較後日期)下午四時正或之前，供股之條件未獲達成或包銷商終止包銷協議，則供股將不會進行。任何股東或其他人士擬於直至供股之全部條件獲達成當日(及包銷商終止包銷協議之權利終止當日)買賣或擬買賣股份，及於**2025年10月16日(星期四)**至**2025年10月30日(星期四)**期間(包括首尾兩日)買賣未繳股款供股股份，將須承擔供股可能不會成為無條件或可能不會進行之風險。建議任何買賣或擬買賣股份或未繳股款供股股份之股東或其他人士諮詢彼等本身之專業顧問。

本額外申請表格及據此提出之所有申請均須受香港法例監管並按其詮釋。

PROCEDURES FOR APPLICATION

This EAF should be completed, signed and lodged, together with payment by cheque or banker's cashier order as to HK\$2.5 per Rights Share for the number of excess Rights Shares applied for, with the Registrar, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17/F, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, so as to be received by no later than 4:00 p.m. on Tuesday, 4 November 2025 (or, under bad weather conditions, such later date as mentioned in the paragraph headed "Effect of Bad Weather" in the enclosed sheet). All remittances must be made in Hong Kong dollars and cheques must be drawn on an account with, or banker's cashier orders must be issued by, a licensed bank in Hong Kong and made payable to "**IMMUNOTECH BIOPHARM LTD – EAF**" and crossed "**Account Payee Only**". All enquiries in connection with this EAF should be addressed to the Registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong. It should be noted that the lodging of this EAF does not assure you of being allocated any Rights Shares in excess of those of your provisional allotments.

All cheques and banker's cashier orders will be presented for payment immediately upon receipt and all interest earned on such application monies (if any) will be retained for the benefit of the Company. Completion and return of this form together with a cheque or banker's cashier order in payment for the excess Rights Shares applied for will constitute a warranty by you that the cheque or banker's cashier order will be honoured on first presentation. If any cheque or banker's cashier order accompanying this form is dishonored on first presentation, this form is liable to be rejected. You must pay the exact amount payable upon application for the excess Rights Shares, and underpaid application will be rejected.

The Company will notify the Qualifying Shareholders the allocation result of the excess application for Rights Shares on Wednesday, 12 November 2025 by way of announcement. If no excess Rights Shares are allotted to you, it is expected that the amount tendered on application will be returned by refund cheque to you in full by ordinary post at your own risk on or before Thursday, 13 November 2025. If the number of excess Rights Shares allotted to you is less than that applied for, it is expected that the surplus application monies will be returned by refund cheque to you by ordinary post at your own risk on or before Thursday, 13 November 2025. Any such cheque(s) will be drawn in favour of the person named on this form (or in case of joint applicants, the first-named applicant). It is expected that certificates in respect of the excess Rights Shares will be posted to you by ordinary post at your own risk on or before Thursday, 13 November 2025. You, except HKSCC Nominees Limited, will receive one share certificate for the entitlement to the Rights Shares in fully-paid form.

DISTRIBUTION OF THIS EAF AND THE OTHER PROSPECTUS DOCUMENTS

This EAF shall only be sent to the Qualifying Shareholders. The Prospectus Documents have not been and will not be registered under any applicable securities of any jurisdictions other than Hong Kong.

No action has been taken to permit the offering of the Rights Shares, or the distribution of the Prospectus Documents, in any territory other than Hong Kong. Accordingly, no person receiving a copy of any of the Prospectus Documents in any territory outside Hong Kong may treat it as an offer or invitation to apply for excess Rights Shares, unless in a territory such an offer or invitation could lawfully be made without compliance with any registration or other legal or regulatory requirements thereof.

It is the responsibility of anyone outside Hong Kong wishing to make on his/her/its/their behalf an application for the Rights Shares to satisfy himself/herself/itself/themselves as to the full observance of the applicable laws and regulations of the relevant jurisdictions including obtaining of any governmental or other consents and to pay any taxes and duties. By completing, signing and submitting this EAF, each subscriber of the Rights Shares will be deemed to have given a warranty to the Company and the Underwriter that these local registration, legal and regulatory requirements have been fully complied with. For the avoidance of doubt, neither HKSCC nor HKSCC Nominees Limited is subject to any of the representations and warranties. If you are in any doubt as to your position, you should consult your professional advisers.

申請手續

本額外申請表格須填妥及簽署，並連同按申請額外供股股份數目支付每股供股股份2.5港元的款項的支票或銀行本票，在不遲於2025年11月4日(星期二)(或於惡劣天氣情況下，附頁「惡劣天氣之影響」一段所述之較後日期)下午四時正前交回過戶登記處香港中央證券登記有限公司(地址為香港灣仔皇后大道東183號合和中心17樓1712-1716號舖)。所有股款須以港元繳付，支票必須由香港持牌銀行之銀行戶口開出，而銀行本票則須由香港持牌銀行發出，註明抬頭人為「**IMMUNOTECH BIOPHARM LTD – EAF**」，並以「**只准入抬頭人賬戶**」方式劃線開出。所有有關本額外申請表格的查詢均須寄交過戶登記處香港中央證券登記有限公司(地址為香港灣仔皇后大道東183號合和中心17M樓)。務請注意，交回本額外申請表格並不保證閣下將獲配發超出閣下暫定配額之任何供股股份。

所有支票及銀行本票將於收到後隨即兌現，而有關申請股款所賺取之全部利息(如有)將撥歸本公司所有。填妥本表格並連同支付所申請額外供股股份股款之支票或銀行本票一併交回，即表示閣下保證支票或銀行本票將於首次過戶時兌現。倘隨附本表格之任何支票或銀行本票於首次過戶時未能兌現，本表格會遭拒絕受理。閣下須於申請額外供股股份時支付應付準確金額，支付金額不足的申請會遭拒絕受理。

本公司將於2025年11月12日(星期三)以公告方式通知合資格股東額外申請供股股份之分配結果。倘閣下不獲配發額外供股股份，則預期於申請時繳付之股款將於2025年11月13日(星期四)或之前以平郵寄出退款支票全數退還予閣下，郵誤風險概由閣下自行承擔。倘閣下獲配發之額外供股股份少於所申請之數目，則預期多繳之申請股款將於2025年11月13日(星期四)或之前以平郵寄出退款支票退還予閣下，郵誤風險概由閣下自行承擔。任何有關支票將以名列本表格之人士(或倘為聯名申請人，則為排名首位之申請人)為收款人。額外供股股份之股票預期將於2025年11月13日(星期四)或之前以平郵寄出，郵誤風險概由閣下自行承擔。閣下(香港中央結算(代理人)有限公司除外)將會就繳足股款供股股份之配額獲發一張股票。

派發本額外申請表格及其他章程文件

本額外申請表格只可向合資格股東寄發。章程文件並無且將不會根據香港以外任何司法權區之任何適用證券法例登記。

本公司並無採取任何行動，以獲准在香港以外任何地區提呈發售供股股份或派發章程文件。因此，任何人士如在香港以外任何地區接獲任何章程文件文本，除非在該地區可合法提呈有關要約或邀請而毋須遵守其任何登記或其他法律或監管規定，否則不可視作提呈申請額外供股股份之要約或邀請。

任何身處香港以外地區之人士如有意申請供股股份，有責任自行全面遵守有關司法權區之適用法律及法規，包括取得任何政府或其他方面同意及繳付任何稅項及徵費。填妥、簽署及交回本額外申請表格後，供股股份之每名認購人將被視為已向本公司及包銷商保證，彼等已全面遵守該等地方登記、法律及監管規定。為免生疑問，香港結算及香港中央結算(代理人)有限公司概不受限於任何聲明及保證。倘閣下對本身之情況有任何疑問，應諮詢閣下之專業顧問。

TERMINATION OF THE UNDERWRITING AGREEMENT

The Underwriter shall be entitled by giving notice in writing to the Company prior to the Latest Time for Termination to terminate the Underwriting Agreement, if:

- (a) there occurs any new regulation or any change in the existing law or regulation (or the judicial interpretation thereof) or other occurrence of any nature whatsoever which may in the reasonable opinion of the Underwriter materially and adversely affect the business or the financial or trading position or prospects of the Group as a whole; or
- (b) there occurs any local, national or international event or change, whether or not forming part of a series of events or changes occurring or continuing before, or after the date hereof, of a political, military, financial, economic or other nature (whether or not ejusdem generis with any of the foregoing), or in the nature of any local, national or international outbreak or escalation of hostilities or armed conflict, or affecting local securities markets which may, in the reasonable opinion of the Underwriter, materially and adversely affect the business or the financial or trading position or prospects of the Group as a whole; or
- (c) any material adverse change in the business or in the financial or trading position of the Group as a whole; or
- (d) any material adverse change in market conditions (including, without limitation, a change in fiscal or monetary policy or foreign exchange or currency markets, suspension or restriction of trading in securities) which, in the reasonable opinion of the Underwriter, makes it inexpedient or inadvisable to proceed with the Rights Issue.

Upon giving of notice pursuant to the Underwriting Agreement, the obligations of the Underwriter and the Company under the Underwriting Agreement shall terminate forthwith provided that the Company shall remain liable to pay to the Underwriter such fees and expenses (other than the underwriting commission) payable by the Company pursuant to the Underwriting Agreement. If the Underwriter exercises such right, the Rights Issue will not proceed.

If the Underwriter terminates the Underwriting Agreement, the Rights Issue will not proceed.

If the Underwriter exercises the right to terminate the Underwriting Agreement or if any of the conditions of the Rights Issue as set out in the section headed “Letter from the Board – Conditions of the Rights Issue” in the Prospectus is not fulfilled at or before the time and date specified in the Underwriting Agreement, and the monies received in respect of acceptances of the Rights Shares will be returned to you or such other persons to whom the Rights Shares in their nil-paid form have been validly transferred or, in the case of joint acceptances, to the first-named person without interest, by means of cheques despatched by ordinary post at your own risk to your respective registered addresses by the Registrar on or before Thursday, 13 November 2025.

EFFECT OF BAD WEATHER

The latest time for acceptance of and payment for Rights Shares will not take place if there is a tropical cyclone warning signal no. 8 or above, or a “black” rainstorm warning and/or “extreme conditions” as announced by the Hong Kong Government:

- (i) in force in Hong Kong at any local time before 12:00 noon and no longer in force after 12:00 noon on the Latest Acceptance Date. Instead the latest time for acceptance of and payment for the Rights Shares will be extended to 5:00 p.m. on the same day; and
- (ii) in force in Hong Kong at any local time between 12:00 noon and 4:00 p.m. on the Latest Acceptance Date. Instead the latest time of acceptance of and payment for the Rights Shares will be rescheduled to 4:00 p.m. on the following Business Day which does not have either of those warnings in force at any time between 9:00 a.m. and 4:00 p.m.

If the latest time for acceptance of and payment for the Rights Shares does not take place on the Latest Acceptance Date, the dates mentioned in the section headed “Expected timetable for the Rights Issue” in the Prospectus may be affected. The Company will notify the Shareholders by way of announcement(s) of any change to the expected timetable as soon as practicable.

終止包銷協議

倘發生下列各項，包銷商有權有權在最後終止時限前向本公司發出書面通知終止包銷協議：

- (a) 出現任何新法規或現時之法例或法規(或其有關司法詮釋)出現任何變動或出現任何其他事故(不論其性質)，而包銷商合理認為可能令本集團之整體業務或財務或貿易狀況或前景受到重大不利影響；或
- (b) 任何地方、國家或國際間發生有關政治、軍事、金融、經濟或其他性質(無論是否與任何上述者屬同一類別)之事件或變動(無論是否在包銷協議日期之前及／或之後發生或持續發生之一連串事件或變動其中一部分)，或任何地方、國家或國際間爆發敵對衝突或武裝衝突或衝突升級，或發生影響本地證券市場之事件，而包銷商合理認為可能令本集團整體業務或財務或貿易狀況或前景受到重大不利影響；或
- (c) 本集團整體業務或財務或貿易狀況出現任何重大不利變動；或
- (d) 市場狀況(包括但不限於金融或貨幣政策，或外匯或貨幣市場變動、證券買賣被暫停或受到限制)出現任何重大不利變動，而包銷商合理認為導致其不適宜或不應進行供股。

於根據包銷協議發出通知後，包銷商及本公司於包銷協議項下之義務將即時終止，惟本公司仍有責任向包銷商支付本公司根據包銷協議應付之有關費用及開支(包銷佣金除外)。倘包銷商行使有關權利，供股將不會進行。

倘包銷商終止包銷協議，供股則不會進行。

倘包銷商行使權利終止包銷協議或倘供股章程「董事會函件－供股的條件」一節所載之任何供股之條件未能於包銷協議訂明之時間及日期或之前達成，則過戶登記處將就接納供股股份所收取之款項於2025年11月13日(星期四)或之前不計利息以支票方式退還予閣下或已獲有效轉讓未繳股款供股股份之其他人士(或倘為聯名接納人，則為名列首位之人士)，並以平郵方式寄往閣下各自之登記地址，郵誤風險概由閣下自行承擔。

惡劣天氣之影響

倘於下列時間懸掛八號或以上熱帶氣旋警告訊號或「黑色」暴雨警告訊號及／或出現香港政府所宣佈「極端情況」，則接納供股股份及繳付股款之最後時限將不會落實：

- (i) 於最後接納日期中午十二時正前任何本地時間在香港生效，並於中午十二時正後不再生效。接納供股股份及繳付股款之最後時限將延至同日下午五時正；及
- (ii) 於最後接納日期中午十二時正至下午四時正期間任何本地時間在香港生效。接納供股股份及繳付股款之最後時限將改為下一個於上午九時正至下午四時正期間任何時間並無該等警告生效之營業日下午四時正。

倘接納供股股份及繳付股款之最後時限並無於最後接納日期落實，則供股章程所載「供股之預期時間表」一節所述日期或會受到影響。本公司將於實際可行情況下儘快以公告方式知會股東有關預期時間表之任何變動。

GENERAL

References in this EAF to times and dates are to Hong Kong times and dates unless otherwise stated.

By completing, signing and submitting this EAF, you agree to disclose to the Company and/or the Registrar and/or their respective advisers and agent's personal data and any information which they require about you or the person(s) for whose benefit you have made the application for excess Rights Shares. The Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the “**Ordinance**”) provides the holders of securities with rights to ascertain whether the Company or the Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. In accordance with the Ordinance, the Company and the Registrar have the right to charge a reasonable fee for the processing of any data access request. All requests for access to data or correction of data or for information regarding policies and practices and the kinds of data held should be addressed to (i) the Company, at its principal office at 31/F, Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong or as notified from time to time in accordance with applicable law, for the attention of the company secretary of the Company; or (ii) (as the case may be) the Registrar at its address set out above.

A SEPARATE CHEQUE OR BANKER'S CASHIER ORDER MUST ACCOMPANY EACH APPLICATION
NO RECEIPT WILL BE GIVEN FOR REMITTANCE

一般事項

除另有說明者外，本額外申請表格內所提及之時間及日期為香港時間及日期。

填妥、簽署及交回本額外申請表格，即表示閣下同意向本公司及／或過戶登記處及／或彼等各自的顧問及代理披露個人資料及彼等所需而有關於閣下或閣下為其利益而申請額外供股股份的人士的任何資料。香港法例第486章個人資料(私隱)條例(「該條例」)給予證券持有人權利可確定本公司或過戶登記處是否持有其個人資料，索取有關資料的文本，以及改正任何不準確的資料。根據該條例，本公司及過戶登記處有權就處理任何查閱資料的要求收取合理費用。有關查閱資料或改正資料或有關政策及慣例以及持有資料種類的資料的所有要求，應寄往(i)本公司根據適用法律不時通知的主要辦事處(地址為香港銅鑼灣勿地臣街1號時代廣場二座31樓)，並以本公司公司秘書為收件人；或(ii)(視情況而定)過戶登記處(地址見上文)。

每份申請須隨附獨立開出的支票或銀行本票
本公司將不另發股款收據